Sudeep Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0QPI01025
  • NSEID: SUDEEPPHRM
  • BSEID: 544619
INR
665.30
27.25 (4.27%)
BSENSE

Feb 09

BSE+NSE Vol: 1.61 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Cr
Consolidate Quarterly Results
Dec'25
Sep'25
Jun'25
Dec'24
Sep'24
Net Sales
172.34
162.67
124.92
115.54
148.80
Other Operating Income
0.00
0.00
0.00
0.00
0.00
Total Operating income
172.34
162.67
124.92
115.54
148.80
Raw Material Cost
70.26
70.48
57.63
51.63
52.15
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
-10.07
-9.54
-15.31
-13.68
-2.48
Employee Cost
15.04
14.10
12.24
9.68
9.20
Power Cost
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
-0.01
0.01
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
Other Expenses
37.14
32.17
26.48
28.62
26.45
Total Expenditure (Excl Depreciation)
112.37
107.21
81.04
76.24
85.33
Operating Profit (PBDIT) excl Other Income
59.97
55.46
43.88
39.30
63.47
Other Income
6.84
10.17
5.16
2.44
1.87
Operating Profit (PBDIT)
66.81
65.63
49.04
41.74
65.34
Interest
1.17
2.28
1.71
1.41
1.05
Exceptional Items
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
65.64
63.35
47.33
40.33
64.29
Depreciation
3.86
3.81
3.25
2.67
2.58
Profit Before Tax
61.78
59.53
44.07
37.66
61.72
Tax
14.08
12.76
12.80
8.94
12.97
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
Profit After Tax
47.70
46.78
31.27
28.71
48.75
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
Net Profit
47.70
46.78
31.27
28.71
48.75
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.24
1.03
0.46
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
47.46
45.75
30.81
28.71
48.75
Equity Capital
11.29
9.72
9.72
9.72
3.80
Face Value
1.0
1.0
1.0
1.0
1.0
Reserves
0.00
0.00
0.00
0.00
0.00
Earnings per share (EPS)
4.2
4.71
3.17
0.3
0.58
Diluted Earnings per share
4.29
4.2
2.84
0.27
0.2
Operating Profit Margin (Excl OI)
34.8%
34.09%
35.13%
34.01%
42.65%
Gross Profit Margin
38.09%
38.94%
37.89%
34.91%
43.21%
PAT Margin
27.68%
28.76%
25.03%
24.85%
32.76%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Dec 2025 is 2.73% vs 9.62% in Sep 2025

stock-summary

Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -9.65% vs 18.02% in Sep 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Dec 2025 is -4.08% vs 1.58% in Sep 2025

stock-summary

Interest

QoQ Growth in quarter ended Dec 2025 is -68.97% vs 40.97% in Sep 2025

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

Compare Quarterly Results Of Sudeep Pharma With
Markets Mojo
Figures in Cr
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
172.34
1,017.53
-845.19
-83.06%
Other Operating Income
0.00
0.00
0.00
Total Operating income
172.34
1,017.53
-845.19
-83.06%
Raw Material Cost
70.26
552.63
-482.37
-87.29%
Purchase of Finished goods
0.00
56.71
-56.71
-100.00%
(Increase) / Decrease In Stocks
-10.07
-16.77
6.70
39.95%
Employee Cost
15.04
189.27
-174.23
-92.05%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
-0.01
0.01
100.00%
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
37.14
141.23
-104.09
-73.70%
Total Expenditure (Excl Depreciation)
112.37
923.06
-810.69
-87.83%
Operating Profit (PBDIT) excl Other Income
59.97
94.47
-34.50
-36.52%
Other Income
6.84
32.37
-25.53
-78.87%
Operating Profit (PBDIT)
66.81
126.84
-60.03
-47.33%
Interest
1.17
23.30
-22.13
-94.98%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
65.64
103.54
-37.90
-36.60%
Depreciation
3.86
37.86
-34.00
-89.80%
Profit Before Tax
61.78
65.67
-3.89
-5.92%
Tax
14.08
22.98
-8.90
-38.73%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
47.70
42.70
5.00
11.71%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
47.70
42.70
5.00
11.71%
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
0.24
1.91
-1.67
-87.43%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
47.46
40.78
6.68
16.38%
Equity Capital
11.29
30.62
-19.33
-63.13%
Face Value
1.00
2.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
4.20
2.66
1.54
57.89%
Diluted Earnings per share
4.29
2.66
1.63
61.28%
Operating Profit Margin (Excl OI)
34.80%
9.28%
0.00
25.52%
Gross Profit Margin
38.09%
10.18%
0.00
27.91%
PAT Margin
27.68%
4.20%
0.00
23.48%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Quarterly - Net Sales
Net Sales 90.28 Cr
in Dec 2025

Figures in Cr
stock-summary

QoQ Growth in quarter ended Dec 2025 is 2.73% vs 9.62% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 8.15%

Quarterly - Standalone Net Profit
Standalone Net Profit 26.87 Cr
in Dec 2025

Figures in Cr
stock-summary

QoQ Growth in quarter ended Dec 2025 is -9.65% vs 18.02% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 30.25%

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 29.61 Cr
in Dec 2025

Figures in Cr
stock-summary

QoQ Growth in quarter ended Dec 2025 is -4.08% vs 1.58% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 11.90%

Quarterly - Interest
Interest 0.63 Cr
in Dec 2025

Figures in Cr
stock-summary

QoQ Growth in quarter ended Dec 2025 is -68.97% vs 40.97% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is -49.60%

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 32.80%
in Dec 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 has improved from Dec 2024